Through a series of CRISPR/Cas9 knockout library screens together with RNA-seq and metabolomics analyses, we identified PSTK, which is a pivotal intermediate involved in selenocysteine biosynthesis [20], as a key mediator of HCC cell targeted therapy resistance. This evidence concerns the gene PSTK and hepatocellular carcinoma.